Objectives: The full crossmatch is traditionally the final step in compatibility testing, acting as a serologic double check for ABO compatibility and unexpected RBC antibodies. In this review, we discuss the development of electronic crossmatch (EXM), an approach for determining when EXM can be used, and its strengths and weaknesses. Methods: Because EXM relies on highly sensitive screening assays, antibodies are frequently encountered whose clinical significance must be investigated and interpreted. Our approach is to obtain further history, perform enhanced tube testing, and consider tests of immune reactivity or RBC survival. Results: For those without clinically significant antibodies, we found two alternatives: immediate-spin crossmatch (IS XM) and EXM. IS XM is prone to error related to serologic interference, whereas EXM depends on the accuracy of the sample label, accurate data entry, and informatics to avoid errors. Conclusion: EXM is an alternative to the serologic test in patients who have no clinically significant antibodies.
CITATION STYLE
Mazepa, M. A., Raval, J. S., & Park, Y. A. (2014, May 1). Pathology consultation on electronic crossmatch. American Journal of Clinical Pathology. Oxford University Press. https://doi.org/10.1309/AJCPZRQIPGZ2XU4V
Mendeley helps you to discover research relevant for your work.